The Long Run with Luke Timmerman
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
May 20, 2024
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, discuss using synthetic biology and AI for drug discovery. They explore yeast as a platform, business representation challenges, and innovative approaches to developing antibodies. The podcast dives into how AI revolutionizes drug discovery and optimization, impacting human health through unique biological understanding.
01:00:44
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- A-Alpha Bio utilizes synthetic biology and AI for drug discovery focusing on protein-protein interactions.
- Their data-driven platform with AI integration revolutionizes drug development workflows.
Deep dives
A.A.L. Fabio's Innovative Approach to Protein-Protein Interactions
A.A.L. Fabio, a Seattle-based company, specializes in high-volume synthetic biology to analyze protein-protein interactions using machine learning. Their sin-bio and AI technologies help identify drug candidates with specific optimal characteristics, like high-affinity binding to particular epitopes. Collaborating with industry giants like Gilead Sciences, Amgen, and Bristol Myers-Squibb, they work on developing molecular glue therapies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
